The American Institute for Medical and Biological Engineering (AIMBE) has presented its highest honor, the Pierre Galletti Award, to Scott P. Bruder, MD, PhD ’84. The award is named for the late Pierre M. Galletti, renowned biomedical engineer and the first vice president of biology and medicine at Brown.
As an undergraduate concentrator in biology at Brown, Bruder studied under Dr. Galetti. He has the distinction of being the first of Galletti’s former students to be given the titular honor. In receiving the award, Bruder said “I have had the distinct honor of being mentored by many great leaders, including Dr. Galletti, who taught a generation of investigators to demand scientific excellence, reduce their discoveries to practice, strive to impact patient care globally, and learn, teach and pay these lessons forward.”
The award recognizes Bruder’s scholarship and innovation in biotechnology, medical device and diagnostic products, as well as his efforts in biomedical education and public policy. Bruder serves as an adjunct professor of biomedical engineering at Case Western Reserve University and leads his own consulting firm, Bruder Consulting International. Read more…
WASHINGTON, D.C. – The American Institute for Medical and Biological Engineering (AIMBE) has selected Scott P. Bruder, MD, PhD, as the 2015 recipient of the Pierre Galletti Award. The Galletti Award is the highest honor that AIMBE bestows on an individual. Dr. Bruder has contributed to the advancement of human health through research and commercialization of biotech, medical device and diagnostic products, and successfully connected industry and academic expertise to influence biomedical education training programs and the public policies required to support success of these bench-to-bedside endeavors. Dr. Bruder has a long and proven track record of performance across multiple roles in his career, and is an accomplished scholar and innovator with more than 20 issued patents, nearly 150 original articles, book chapters and abstracts, and many notable awards from professional societies, universities and industry organizations.
Scott Bruder, M.D., Ph.D. has been a professor of biomedical engineering, an FDA Advisory Panel member, chief science and technology officer and a seasoned science executive with Becton, Dickinson and Company, DePuy, Inc., Anika Therapeutics, Inc. and Osiris Therapeutics, Inc.
The new leaders at Stryker Corporation took notice and convinced Bruder to fill a new position at the company, Vice President, Chief Medical and Scientific Officer.
The company announced the appointment on January 7, 2013.
Kevin Lobo, Stryker’s relatively new president and CEO, said Bruder’s addition to the executive leadership team will “further broaden our clinical and scientific expertise while also strengthening our capabilities in the critical areas of evidence-based medicine.”
In this role, Bruder will oversee the company’s clinical and scientific efforts, including academic, industrial and governmental scientific partnerships. In addition, according to the company announcement, he will represent Stryker as the leading medical authority of the company for trade associations, regulatory bodies, and other entities while also partnering with teams across the organization.
Stryker Corporation (NYSE:SYK) announced that Scott P. Bruder, MD, PhD has joined the Company in the newly created position of Vice President, Chief Medical and Scientific Officer, reporting to Kevin A. Lobo, President and Chief Executive Officer. In this role, Dr. Bruder will oversee the clinical and scientific efforts of Stryker Corporation, including academic, industrial and governmental scientific partnerships. In addition, he will represent Stryker as the leading medical authority of the Company for trade associations, regulatory bodies, and other entities while also partnering with our teams across the organization.
Dr. Bruder has a long and distinguished track record of performance with more than 20 issued and pending patents, nearly 150 publications and numerous honors from the American Academy of Orthopaedic Surgeons, the Orthopaedic Research Society and the Association of Bone and Joint Surgeons. For the past five years, Dr. Bruder worked at Becton, Dickinson and Company as the Chief Science and Technology Officer, where he was responsible for identifying and cultivating new growth opportunities, improving the product development system and enhancing global research capabilities. Prior to that, Dr. Bruder spent 8 years at Johnson & Johnson in a series of senior executive and scientific roles in various businesses. Earlier in his career, Dr. Bruder held leadership roles at Anika Therapeutics and Osiris Therapeutics.